Recombinant bacillus subtilis with IL-6R nano antibody secretion function as well as construction method and application thereof

The recombinant Bacillus subtilis constructed through gene editing uses the amyE gene locus of Bacillus subtilis WB800N to integrate the NbIL6R gene, which solves the poor targeting and serious systemic response in IBD treatment, and achieves safe and efficient IL-6R nanoantibodies secretion , relieves inflammatory bowel disease symptoms and reduces the disease activity index.

CN119020389APending Publication Date: 2024-11-26JIANGSU PROVINCE HOSPITAL (THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY)
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202411174646.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-26
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The existing IBD treatment methods have problems with poor targeting and serious systemic response, and the traditional intravenous administration of monoclonal antibodies is not suitable, and there is a lack of safe and efficient treatment plans.

Method used

Gene editing to construct recombinant Bacillus subtilis with IL-6R nanoantibodies secretion function, use the amyE gene locus of Bacillus subtilis WB800N to integrate the NbIL6R gene, and mediate the secretion of IL-6R nanoantibodies through the promoter Pac and signal peptide SPAprE. Expressed to form recombinant Bacillus subtilis to treat inflammatory bowel disease.

Benefits of technology

This method can effectively alleviate weight loss, colon shortening and intestinal mucosa caused by inflammatory bowel disease, reduce disease activity index and the content of proinflammatory cytokines, regulate the composition of intestinal immune cells, and has no toxic side effects on internal organs. It provides a A safe and efficient treatment plan.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119020389A_ABST
    Figure CN119020389A_ABST
Patent Text Reader

Abstract

The invention discloses recombinant bacillus subtilis with an IL-6R nano antibody secretion function as well as a construction method and application of the recombinant bacillus subtilis, and relates to the field of biotechnology and medicine. The construction method comprises the following steps: integrating an expression cassette of an NbIL6R gene to an amyE gene locus of bacillus subtilis WB800N, and constructing to obtain the recombinant bacillus subtilis, the nucleotide sequence of the NbIL6R gene is as shown in SEQ ID NO. 1. The recombinant bacillus subtilis can relieve weight loss and intestinal mucosa damage caused by the inflammatory bowel disease, reduce the disease activity index and the content of proinflammatory cytokines, and regulate the composition of intestinal immune cells, thereby effectively treating the inflammatory bowel disease. Besides, the recombinant bacillus subtilis is free of toxic and side effects, can relieve damage to colon tissue, is a safe and efficient product for treating the inflammatory bowel disease and related intestinal inflammation, and has a great application prospect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the fields of biotechnology and medicine, and in particular to a recombinant Bacillus subtilis having the function of secreting IL-6R nano-antibody and a construction method and application thereof. Background Art

[0002] Inflammatory bowel disease (IBD) is a type of chronic inflammatory disease of the digestive tract characterized by chronic idiopathicity, which can affect the colon mucosa or the entire gastrointestinal tract. The clinical symptoms of the disease are mainly manifested as enteritis, diarrhea, and recurrent bleeding, which may even cause further disability. In addition, inflammatory bowel disease has the potential risk of developing into cancer, mainly including colorectal cancer and lymphoma. The main hypothesis about the pathogenesis of IBD points out that the causes of IBD are complex and involve immune dysfunction, genetic susceptibility and environmental factors, including intestinal inflammation, mucosal barrier function and bacterial flora. Although there are currently a variety of therapeutic drugs that can help control the symptoms of IBD, such as aminosalicylic acid preparations and corticosteroids, these drugs can produce serious side effects while exerting their efficacy. Long-term use will lead to a decrease in the body's immunity, making it more susceptible to infection and having adverse effects on health. With the advancement of antibody preparation technology, more and more biological agents (such as infliximab, ustekinumab, vedolizumab, Janus kinase inhibitors) are also used to treat IBD. However, due to the intravenous administration of monoclonal antibodies, there are problems of poor targeting and severe systemic reactions in actual use. Therefore, it is very important to study a new IBD treatment method with excellent targeting and safety.

[0003] Nanobodies, also known as VHH, are ultra-small antibodies derived from a heavy-chain antibody in the serum of camelids. It contains only the variable region of the heavy chain of traditional monoclonal antibodies, consisting of 4 framework regions (FR) and 3 hypervariable regions (CDR), and the general molecular weight is only about 15kDa. Because its size can reach the nanometer level, it has the advantages of high penetration, high stability, low immunogenicity, and low production cost compared with full-length monoclonal antibodies. And because of the simple sequence, mass production can be achieved by microbial gene editing. Bacillus subtilis is a new type of Gram-positive probiotic, which is commonly used to prepare various microbial supplements. It is also a commonly used gene editing vector with the characteristics of mature expression system and strong secretion ability. The present invention intends to cultivate an engineered bacterium that can continuously secrete IL-6R nanoantibody protein by gene editing of Bacillus subtilis, thereby providing technical support for the treatment of inflammatory bowel disease. Summary of the invention

[0004] The purpose of the present invention is to provide a recombinant Bacillus subtilis with IL-6R nanobody secretion function and a construction method thereof to solve the problems existing in the above-mentioned prior art. The recombinant Bacillus subtilis provided by the present invention can effectively treat inflammatory bowel disease, has no toxic side effects, and has the advantages of safety and high efficiency.

[0005] To achieve the above object, the present invention provides the following solutions:

[0006] The present invention provides a method for constructing a recombinant Bacillus subtilis having an IL-6R nanobody secretion function, comprising the steps of integrating an expression cassette of the NbIL6R gene into the amyE gene site of Bacillus subtilis WB800N to construct the recombinant Bacillus subtilis;

[0007] The nucleotide sequence of the NbIL6R gene is shown in SEQ ID NO.1.

[0008] Furthermore, the construction method specifically comprises the following steps:

[0009] Using the total genome of Bacillus subtilis WB800N as a template, primer pairs P1 / P2 and P9 / P10 were used to amplify the upstream homology arm LF fragment and the downstream homology arm RF fragment of the amyE gene respectively;

[0010] The SPC fragment was amplified using primer pair P3 / P4 using pDG1730 plasmid as template;

[0011] Using the total genome of Bacillus subtilis PD8SPAprE-MFP3 as a template, primer pairs P5 / P6 and P7 / P8 were used to amplify the Pac-SPAprE fragment and the fragment containing the NbIL6R gene.

[0012] The LF fragment, the SPC fragment, the Pac-SPAprE fragment, the fragment containing the NbIL6R gene and the RF fragment are fused by overlapping extension PCR to obtain a fusion fragment L-SPC-Pac-SPAprE-NbIL6R-RF; the fusion fragment L-SPC-Pac-SPAprE-NbIL6R-RF is transformed into Bacillus subtilis WB800N competent cells, and the recombinant Bacillus subtilis is obtained by screening with spectinomycin;

[0013] The nucleotide sequences of P1, P2, P3, P4, P5, P6, P7, P8, P9 and P10 are shown in SEQ ID NOs. 2-11, respectively.

[0014] The present invention also provides a recombinant Bacillus subtilis constructed according to the above construction method.

[0015] The present invention also provides the use of the recombinant Bacillus subtilis in preparing a medicine for treating inflammatory bowel disease.

[0016] The present invention also provides a medicine for treating inflammatory bowel disease, wherein the active ingredient comprises the above-mentioned recombinant Bacillus subtilis.

[0017] Furthermore, the medicine also includes pharmaceutically acceptable excipients.

[0018] Furthermore, the auxiliary materials include adhesives, disintegrants, fillers, stabilizers, preservatives, coating materials and / or fragrances.

[0019] Furthermore, the dosage form of the drug is capsule, tablet, granule, emulsion, pill or oral solution.

[0020] The present invention discloses the following technical effects:

[0021] The present invention utilizes the principle of homologous recombination, uses Bacillus subtilis WB800N as a host, constructs an expression cassette of IL-6R nanoantibody and integrates it into the amyE gene site of Bacillus subtilis WB800N, and uses promoter Pac and signal peptide SPAprE to mediate the secretory expression of IL-6R nanoantibody, thereby constructing a recombinant Bacillus subtilis with IL-6R nanoantibody secretion function. The recombinant Bacillus subtilis can alleviate weight loss, colon shortening and intestinal mucosal damage caused by inflammatory bowel disease, reduce the disease activity index (DAI) and the content of proinflammatory cytokines, regulate the composition of intestinal immune cells, and effectively treat inflammatory bowel disease.

[0022] After organ toxicity testing, it was found that the recombinant Bacillus subtilis has no toxic side effects on internal organs and can reduce damage to colon tissue. It is a safe and effective product for the treatment of inflammatory bowel disease and related intestinal inflammation, and has great application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0024] Figure 1The results of SDS-PAGE and Western-Blot verification of the purified IL-6R nanobody protein; wherein A is the SDS-PAGE result of the purified IL-6R nanobody protein; B is the result of Western-Blot verification of the nanobody protein using the BS-IL6NB culture supernatant; C is the result of Western-Blot verification of the nanobody protein using the purified IL-6R nanobody protein;

[0025] Figure 2 The statistical graphs of weight changes of mice in each experimental group;

[0026] Figure 3 This is a statistical chart of the changes in the disease activity index of mice in each experimental group;

[0027] Figure 4 The colon length measurement results of mice in each experimental group; A is the colon length measurement graph; B is the statistical graph of A;

[0028] Figure 5 The colon histopathological score statistics of mice in each experimental group;

[0029] Figure 6 H&E staining images of colon tissues of mice in each experimental group;

[0030] Figure 7 H&E staining images of the lung, liver, kidney, and spleen tissues of mice in the blank group and BS-IL6NB treatment group;

[0031] Figure 8 The following are statistical graphs of the levels of inflammatory factors in the colon and plasma of mice in each experimental group; A is the expression level of IL-1β in the colon; B is the expression level of IL-6 in the colon; and C is the content of IL-6 in plasma;

[0032] Fig. 9 The results of the detection of colon propria mononuclear cells (LPMC) in each experimental group of mice; A is IL17 + Foxp3 + Lymphocyte ratio test results; B is Foxp3 + IL17A-lymphocyte ratio detection results. DETAILED DESCRIPTION

[0033] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.

[0034] It should be understood that the terms described in the present invention are only for describing a particular embodiment and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper and lower limits of the scope is also specifically disclosed. The intermediate value in any stated value or stated range, and each smaller range between any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.

[0035] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.

[0036] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to those skilled in the art. The present invention description and examples are exemplary only.

[0037] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.

[0038] The mice involved in the following embodiments are 6-8 week old male SPF grade C57BL / 6J mice, purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd.; ELISA kits were purchased from Hangzhou Lianke Biotechnology Co., Ltd.; dextran sulfate sodium (DSS) was purchased from Shanghai Aladdin Biochemical Technology Co., Ltd.; Bacillus subtilis WB800N (named BS-WB800N in the present invention) was purchased from Beina Chuanglian Biotechnology Co., Ltd.; Bacillus subtilis PD8SPAprE-MFP3 has been described in the literature "Wu P, Tao Q, Liu Y, Zeng C, Li Y, Yan X. Efficient secretion of mussel adhesion proteins using a chaperone protein Spy as fusion tag in Bacillus subtilis. Biotechnol J. 2023 Oct; 18 (10): e2200582. doi: 10.1002 / biot.202200582. Epub 2023 Jul. 2. PMID: 37357718”, the present invention promises to be released to the public twenty years from the application date of the present invention; pDG1730 plasmid was purchased from Shanghai Yaji Biotechnology Co., Ltd.; pHCMC05 plasmid was purchased from Shanghai Meiyan Biotechnology Co., Ltd.

[0039] The primer sequences involved in the present invention are shown in Table 1.

[0040] Table 1 Primer sequences involved in the present invention

[0041]

[0042] Example 1 Construction of recombinant engineering strain BS-IL6NB

[0043] Using Bacillus subtilis WB800N as the host, promoter Pac and signal peptide SPAprE were used to mediate the secretory expression of NbIL6R. Specifically, in order to construct the expression cassette of the NbIL6R gene and integrate it into the amyE gene site of strain WB800N, the total genome of Bacillus subtilis WB800N was used as a template, and the upstream homology arm LF fragment and the downstream homology arm RF fragment of the amyE gene were amplified using primer pairs P1 / P2 and P9 / P10 respectively;

[0044] Using the pDG1730 plasmid as a template, the SPC fragment (spectinomycin resistance marker) was amplified with primer pair P3 / P4;

[0045] Using the total genome of Bacillus subtilis PD8SPAprE-MFP3 as a template, primer pairs P5 / P6 and P7 / P8 were used to amplify the Pac-SPAprE fragment and the fragment containing the NbIL6R gene.

[0046] The LF fragment, SPC fragment, Pac-SPAprE fragment, the fragment containing the NbIL6R gene and the RF fragment were fused by overlapping extension PCR to obtain the fusion fragment L-SPC-Pac-SPAprE-NbIL6R-RF; the fusion fragment was transformed into the competent cells of the strain WB800N, and the strain BS-IL6NB was obtained by screening with spectinomycin.

[0047] The nucleotide sequence of the NbIL6R gene is shown in SEQ ID NO.1.

[0048] SEQ ID NO.1: GAAGTACAACTTGTAGAATCTGGGGGAGGCCTTGTGCAAGCTGGCG GAAGCTTGCGCTTATCTTGCGGCATCCGGCTCTATCTTTTCCATTAAAGCGATGGGGTGGTTAGACAGGCACCGGGAAAACAAAGAGAATTGGTTGCGCGCACTACTAGCGGAGGTAGCACTTATTATGCTGACTCGGTCAAAGGCCGTTTCACAA TTAGCAGAGATAATGCTAAGAACACGGTCTATCTGCAGATGAATAGTTTAAAACCGGAAGATACAGCAGTCTTCTATTGCAATGCCATCGTCACCGACTCTGATTATGATTTAGGCAATGATTATTGGGGCCAAGGCACTCAGGTGACGGTCTCTAGT.

[0049] Example 2 Construction of strain BS-IL6NB-His

[0050] Using the total genome of strain BS-IL6NB as a template, the primer pairs P1 / P11 and P12 / P10 in Table 1 were used to amplify the fragments LF-SPC-Pac-SPAprE-NbIL6R-His and RF, respectively. The two fragments were fused by overlap extension PCR to obtain the fusion fragment LF-SPC-Pac-SPAprE-NbIL6R-His-RF fragment, and the fusion fragment was transformed into WB800N competent cells and selected with spectinomycin to obtain the strain BS-IL6NB-His.

[0051] Example 3B. Construction of S-IL6NB-Flag-His strain

[0052] Using the total genome of strain BS-IL6NB as a template, the primer pairs P1 / P13 and P14 / P10 in Table 1 were used as primers to amplify the fragments LF-SPC-Pac-SPAprE-NbIL6R-Flag-His and fragment RF, respectively. The two fragments were fused by overlap extension PCR to obtain the fusion fragment LF-SPC-Pac-SPAprE-NbIL6R-Flag-His-RF, and the fusion fragment was transformed into WB800N competent cells and selected with spectinomycin to obtain the strain BS-IL6NB-Flag-His.

[0053] Example 4 Construction of strain BS-IL6NB-Flag-His-sfGFP

[0054] Using pHCMC05 plasmid as template, the linear backbone of plasmid pHCMC05 was amplified using primer pair P17 / P18 in Table 1; the expression cassette fragment Pveg-gfp of sfGFP was amplified using primer pair P15 / P16. Referring to the method for preparing polymers, the linear backbone of pHCMC05 and Pveg-gfp were fused by PCR, and then the fusion fragment was transferred into competent cells of strain BS-IL6NB-Flag-His, and selected with chloramphenicol to obtain strain BS-IL6NB-Flag-His-sfGFP.

[0055] Example 5 Purification and verification of bacterial secreted IL-6R nanobody protein

[0056] The strain BS-IL6NB-Flag-His-sfGFP obtained in Example 4 was expanded and cultured, and the bacterial solution was centrifuged and the supernatant was collected. 2+ -NTA affinity chromatography to purify the protein. Figure 1 As shown, the purified protein was verified by SDS-PAGE and Western-Blot, confirming that the molecular weight of the purified IL-6R nanobody was about 15 kDa.

[0057] Example 6 Animal Experiment

[0058] 1. Experimental Grouping

[0059] C57BL / 6J mice, male, 6-8 weeks old, were purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd., weighing 18-20g. After one week of adaptive feeding, the mice were randomly divided into 4 groups, 5 mice in each group, namely, blank group (H2O), model group (DSS), control group (DSS+Bs WB800N), and BS-IL6NB treatment group (DSS+Bs IL6NB). Except for the blank group given sterile distilled water, the mice in the other groups freely drank sterile water containing 3% DSS (36-50kDa) for 7 days to establish an inflammatory bowel disease mouse model.

[0060] The control group and the treatment group drank BS-WB800N or BS-IL6NB (10 9 CFU / mL) of live bacteria in distilled water, as shown in Table 2, and the animal experiment design is as follows:

[0061] Blank group: 1-14 days, free drinking of sterile water.

[0062] Model group: 1-7 days, 3% DSS was used for free drinking water; 8-14 days, sterile water was used for free drinking water.

[0063] Control group: 1-7 days, using BS-WB800N live bacteria (10 9 CFU / mL) of 3% DSS free drinking water; 8-15 days, using BS-WB800N live bacteria (10 9 CFU / mL) of distilled water were given free access to water.

[0064] BS-IL6NB treatment group: Days 1-7, treated with BS-IL6NB live bacteria (10 9 CFU / mL) of 3% DSS free drinking water; 8-15 days, using BS-IL6NB live bacteria (10 9 CFU / mL) of distilled water were given free access to water.

[0065] Table 2 Animal experiment design

[0066]

[0067] On the 15th day of the experiment, blood was collected from mice under anesthesia using sterile tubes. The blood was naturally coagulated at room temperature for 30 minutes, and the mouse serum was collected by centrifugation at 2-8°C for 30 minutes (3000 rpm) and stored at -80°C for later use. The mice were euthanized by CO2, and the lungs, liver, kidneys, spleen and part of the colon tissue were quickly removed, weighed, and fixed with 4% paraformaldehyde. Part of the colon tissue was rinsed with PBS solution, and LPMC was extracted on site. The length from the front end of the mouse cecum to the end of the rectum in the naturally stretched state was measured and recorded with a ruler.

[0068] 2. Index testing and results

[0069] Effects of BS-IL6Nb on DSS-induced IBD in mice

[0070] During the experiment, the weight, stool characteristics and blood in the stool of the mice were recorded, the hair, mental state, food intake and activity of the mice were observed, and the disease activity index was calculated.

[0071] The disease activity index (DAI) scoring standard for inflammatory bowel disease model mice: a comprehensive score is given for the percentage of weight loss (weight unchanged or less than or equal to 1 is 0, greater than 1 and less than or equal to 5 is 1 point, greater than 5 and less than or equal to 10 is 2 points, greater than 10 and less than or equal to 15 is 3 points, and greater than 15 is 4 points), stool consistency (normal is 0, loose stool is 2 points, and diarrhea is 4 points), and stool bleeding (normal is 0, occult blood is 2 points, and overt bleeding is 4 points). The total score of the three results is divided by 3 to obtain the DAI value, that is, DAI = (body weight index + stool shape + bleeding situation) / 3.

[0072] The weight statistics of mice in each group are shown in Figure 2 , Figure 2 The results showed that the inflammatory bowel disease mouse model was successfully established. Except for the blank group (H2O), the body weight of each group showed a significant downward trend. From the 8th day of the experiment, the body weight of the mice in the BS-IL6NB treatment group gradually recovered, while the body weight of the mice in the other groups did not change significantly.

[0073] The statistical results of DAI values ​​of mice in each group are shown in Figure 3 The results showed that the DAI of IBD mice in each group was significantly increased, and BS-IL6NB had a significant effect on reducing the DAI of IBD mice, which had dropped to 0.2 on the 14th day of the experiment, close to the blank group (H2O).

[0074] The results of colon length measurement of mice in each group are shown in Figure 4 The results showed that except for the blank group, drinking 3% DSS caused the colon length of mice with inflammatory bowel disease to be significantly shortened, and the average colon length of mice in the model group (DSS) was only 5.6 cm. The average colon length of mice in the BS-IL6NB treatment group was 6.7 cm, which was close to that of the blank group and significantly different from that of the model group.

[0075] Effects of BS-IL6Nb on colonic pathology in mice with DSS-induced inflammatory bowel disease

[0076] Paraffin tissue sections and H&E staining were used to observe the effects on the mouse colon tissue structure. Figure 6As shown. Observed under a microscope at 50 and 200 times, the colon tissue structure of the blank group (H2O) was normal, the glandular morphology was normal, the goblet cells between the glands were normal, the crypts were normal, and no obvious neutrophil or lymphocyte infiltration and ulcers were observed. In the model group (DSS), the colon mucosa was greatly damaged, the integrity of the mucosa was reduced, a large number of lymphocyte infiltrations could be clearly observed, the number of goblet cells was significantly reduced, the glands disappeared, the crypt structure was destroyed, and the shape was distorted. In the BS-IL6NB treatment group, the colon tissue of the mice had relatively intact mucosal tight junctions, less damage to the goblet cells, almost no crypt destruction, and only a small amount of lymphocyte infiltration.

[0077] The histopathological score was based on five indicators: surface epithelial loss, crypt destruction and inflammatory cell infiltration, lamina propria thickness, and goblet cell reduction. The five indicators were scored from 0 to 4 points according to the degree and severity of the changes: 0, no change; 1, limited and mild; 2, limited and general; 3, extensive and general; 4, extensive and severe. The sum of the scores of these five indicators was defined as the histopathological score. The histopathological score results of each group of mice are shown in Figure 5 The results showed that the average colon histopathology score of mice in the model group (DSS) was 6.9, while the average histopathology score of mice after BS-IL6NB treatment was only 0.4, and the colon pathological changes of inflammatory bowel disease were significantly reversed.

[0078] Effects of BS-IL6Nb on pathology of lung, liver, kidney and spleen in mice with DSS-induced inflammatory bowel disease

[0079] Paraffin tissue sections and H&E staining were used to observe the effects on the tissue structure of the mouse lungs, livers, kidneys, and spleens. Figure 7 .like Figure 7 As shown, under a 50x microscope, after BS-IL6NB treatment, there were no obvious pathological changes in the lungs, livers, and kidneys of mice, but due to intestinal inflammation, the spleen showed loose spleen tissue structure, a little fibrosis, and inflammatory cell infiltration compared with the blank group.

[0080] Effects of BS-IL6Nb on inflammatory factors and intestinal immune cell composition in mice with DSS-induced inflammatory bowel disease

[0081] The levels of inflammatory factors in the colon and plasma of each group of mice were detected and processed as shown in Figure 8 .like Figure 8As shown in the figure, the inflammatory factors IL-1β and IL-6 in the colon homogenate of the model group (DSS) mice were significantly increased compared with those of normal mice (P<0.05). Compared with the model group, BS-IL6NB treatment can significantly reduce the level of inflammatory factors (P<0.05). The level of IL-6 factor in the plasma of the model group (DSS) mice was also significantly increased compared with normal mice, while that of the BS-IL6NB treatment group was significantly lower than that of the model group, and there was no significant difference with the blank group (H2O).

[0082] like Fig. 9 As shown, the pro-inflammatory IL17 was observed in the colonic lamina propria of mice in the model group (DSS) by flow cytometry detection of mouse colonic lamina propria mononuclear cells (LPMC) populations. + Foxp3 + The proportion of lymphocytes was significantly increased compared with the blank group (H2O), while the anti-inflammatory Foxp3 + IL17A - The proportion of lymphocytes was significantly reduced. However, BS-IL6NB treatment increased the expression of IL17 in the intestinal lamina propria. + Foxp3 + The proportion of lymphocytes decreased, while Foxp3 + IL17A - The lymphocyte ratio was significantly restored.

[0083] The embodiments described above are only descriptions of the preferred modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.

Claims

1. A method for constructing a recombinant Bacillus subtilis having the function of secreting IL-6R nanobody, characterized in that: The method comprises the steps of integrating the expression cassette of the NbIL6R gene into the amyE gene site of Bacillus subtilis WB800N to construct the recombinant Bacillus subtilis; The nucleotide sequence of the NbIL6R gene is shown in SEQ ID NO.

1.

2. The construction method according to claim 1, characterized in that: The construction method specifically comprises the following steps: Using the total genome of Bacillus subtilis WB800N as a template, primer pairs P1 / P2 and P9 / P10 were used to amplify the upstream homology arm LF fragment and the downstream homology arm RF fragment of the amyE gene respectively; The SPC fragment was amplified using primer pair P3 / P4 using pDG1730 plasmid as template; Using the total genome of Bacillus subtilis PD8SPAprE-MFP3 as a template, primer pairs P5 / P6 and P7 / P8 were used to amplify the Pac-SPAprE fragment and the fragment containing the NbIL6R gene. The LF fragment, the SPC fragment, the Pac-SPAprE fragment, the fragment containing the NbIL6R gene and the RF fragment are fused by overlapping extension PCR to obtain a fusion fragment L-SPC-Pac-SPAprE-NbIL6R-RF; the fusion fragment L-SPC-Pac-SPAprE-NbIL6R-RF is transformed into Bacillus subtilis WB800N competent cells, and the recombinant Bacillus subtilis is obtained by screening with spectinomycin; The nucleotide sequences of P1, P2, P3, P4, P5, P6, P7, P8, P9 and P10 are shown in SEQ ID NOs. 2-11, respectively.

3. A recombinant Bacillus subtilis constructed according to the construction method according to claim 1 or 2.

4. Use of the recombinant Bacillus subtilis according to claim 3 in the preparation of a medicament for treating inflammatory bowel disease.

5. A drug for treating inflammatory bowel disease, characterized in that: The active ingredient comprises the recombinant Bacillus subtilis according to claim 3.

6. The drug according to claim 5, characterized in that The drug also includes pharmaceutically acceptable excipients.

7. The drug according to claim 6, characterized in that The auxiliary materials include binders, disintegrants, fillers, stabilizers, preservatives, coating materials and / or fragrances.

8. The drug according to claim 6, characterized in that The dosage form of the medicine is capsule, tablet, granule, emulsion, pill or oral solution.

Citation Information

Patent Citations

  • Anti-IL-6R antibody pharmaceutical composition and uses thereof

    CN113713094A

  • Genetic engineering bacillus subtilis capable of efficiently secreting organophosphorus pesticide hydrolase MPH

    CN115717151A

  • Antagonizing interleukin-21 receptor activity

    US20060039902A1

  • Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders

    US20120171209A1

  • Il-6r antibody and antigen binding fragment thereof and medical use

    US20200369774A1